We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Key Takeaways
Hims & Hers Health and Novo Nordisk have announced a partnership to expand obesity care.
Americans will have access to Novo Nordisk's weight loss drug on Hims & Hers' telehealth platform.
The expansion of these medical sector stocks is intriguing, and the partnership could accelerate their growth.
Medical pioneers Hims & Hers Health (HIMS - Free Report) and Novo Nordisk (NVO - Free Report) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
The long-term collaboration will allow millions of Americans to access Novo Nordisk’s FDA-approved weight loss drug Wegovy on Hims & Hers' innovative subscription-based telehealth platform with 24/7 care, clinical support, and nutrition guidance.
HIM & NVO Stock Performance Overview
With the initial announcement of the Novo Nordisk partnership causing a surge in Hims & Hers stock, HIM shares have now soared over +30% in 2025. However, Novo Nordisk stock has fallen more than 20% year to date as the company hopes to regain control of the weight-loss drug market from competitors such as Eli Lilly (LLY - Free Report) .
Amid weak U.S. prescription data for Wegovy, Novo Nordisk stock has vastly trailed Eli Lilly’s YTD gains of +16%. Notably, Novo Nordisk stock is only up +15% in the last three years, which has noticably trailed the broader market and Eli Lilly’s +209%, with Hims & Hers shares soaring over +600%.
Image Source: Zacks Investment Research
Attractive Growth Trajectories
Leading to the stellar price performance of HIMS is Hims & Hers' rapid expansion since going public in 2020. Hims & Hers total sales are projected to spike 58% in fiscal 2025 to $2.33 billion versus $1.48 billion last year. Plus, FY26 sales are projected to surge another 21% to $2.84 billion.
Surging past the probability line, Hims & Hers' annual earnings are expected to skyrocket over 160% this year to $0.72 per share from EPS of $0.27 in 2024. More intriguing, FY26 EPS is forecasted to pop another 48% to $1.07.
Image Source: Zacks Investment Research
Despite increased competition in the diabetes and obesity drug care markets, Novo Nordisk’s sales are currently slated to expand 18% in FY25 and are forecasted to increase another 15% in FY26 to $57.1 billion. Furthermore, Novo Nordisk is expected to post 17% EPS growth this year, with annual earnings projected to spike another 22% in FY26 to $4.71 per share.
Image Source: Zacks Investment Research
HIMS & NVO EPS Revisions
Suggesting more upside for Hims & Hers stock is a pleasant trend of positive earnings estimate revisions. To that point, FY25 and FY26 EPS estimates are nicely up in the last three months and have popped 14% and 12% in the last 30 days, respectively.
Image Source: Zacks Investment Research
As for Novo Nordisk, its FY25 EPS estimates are slightly down over the last quarter but are up 1% in the last month. Optimistically, FY26 EPS estimates for Novo Nordisk have remained higher over the last three months and are up 2% in the last 30 days.
Image Source: Zacks Investment Research
Bottom Line
At the moment, Hims & Hers stock sports a Zacks Rank #2 (Buy) with Novo Nordisk landing a Zacks Rank #3 (Hold). The expansion of these medical sector stocks is very intriguing, with Hims & Hers having a clearer growth path, while Novo Nordisk could still face headwinds from increased competition in the weight-loss drug market, in particular.
That said, this partnership should be beneficial to their growth and is expected to provide millions of Americans with more accessible and affordable obesity care treatments.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Key Takeaways
Medical pioneers Hims & Hers Health (HIMS - Free Report) and Novo Nordisk (NVO - Free Report) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
The long-term collaboration will allow millions of Americans to access Novo Nordisk’s FDA-approved weight loss drug Wegovy on Hims & Hers' innovative subscription-based telehealth platform with 24/7 care, clinical support, and nutrition guidance.
HIM & NVO Stock Performance Overview
With the initial announcement of the Novo Nordisk partnership causing a surge in Hims & Hers stock, HIM shares have now soared over +30% in 2025. However, Novo Nordisk stock has fallen more than 20% year to date as the company hopes to regain control of the weight-loss drug market from competitors such as Eli Lilly (LLY - Free Report) .
Amid weak U.S. prescription data for Wegovy, Novo Nordisk stock has vastly trailed Eli Lilly’s YTD gains of +16%. Notably, Novo Nordisk stock is only up +15% in the last three years, which has noticably trailed the broader market and Eli Lilly’s +209%, with Hims & Hers shares soaring over +600%.
Image Source: Zacks Investment Research
Attractive Growth Trajectories
Leading to the stellar price performance of HIMS is Hims & Hers' rapid expansion since going public in 2020. Hims & Hers total sales are projected to spike 58% in fiscal 2025 to $2.33 billion versus $1.48 billion last year. Plus, FY26 sales are projected to surge another 21% to $2.84 billion.
Surging past the probability line, Hims & Hers' annual earnings are expected to skyrocket over 160% this year to $0.72 per share from EPS of $0.27 in 2024. More intriguing, FY26 EPS is forecasted to pop another 48% to $1.07.
Image Source: Zacks Investment Research
Despite increased competition in the diabetes and obesity drug care markets, Novo Nordisk’s sales are currently slated to expand 18% in FY25 and are forecasted to increase another 15% in FY26 to $57.1 billion. Furthermore, Novo Nordisk is expected to post 17% EPS growth this year, with annual earnings projected to spike another 22% in FY26 to $4.71 per share.
Image Source: Zacks Investment Research
HIMS & NVO EPS Revisions
Suggesting more upside for Hims & Hers stock is a pleasant trend of positive earnings estimate revisions. To that point, FY25 and FY26 EPS estimates are nicely up in the last three months and have popped 14% and 12% in the last 30 days, respectively.
Image Source: Zacks Investment Research
As for Novo Nordisk, its FY25 EPS estimates are slightly down over the last quarter but are up 1% in the last month. Optimistically, FY26 EPS estimates for Novo Nordisk have remained higher over the last three months and are up 2% in the last 30 days.
Image Source: Zacks Investment Research
Bottom Line
At the moment, Hims & Hers stock sports a Zacks Rank #2 (Buy) with Novo Nordisk landing a Zacks Rank #3 (Hold). The expansion of these medical sector stocks is very intriguing, with Hims & Hers having a clearer growth path, while Novo Nordisk could still face headwinds from increased competition in the weight-loss drug market, in particular.
That said, this partnership should be beneficial to their growth and is expected to provide millions of Americans with more accessible and affordable obesity care treatments.